232 related articles for article (PubMed ID: 25960213)
1. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Subhani S; Jayaraman A; Jamil K
Biomed Pharmacother; 2015 Apr; 71():37-45. PubMed ID: 25960213
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
Subhani S; Jamil K
Biomed Pharmacother; 2015 Jul; 73():65-74. PubMed ID: 26211584
[TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
5. [Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Furuiye M; Ishiwata N; Jin Y; Miyashita Y; Takano S; Yoshizawa M; Miyake S; Inase N; Yoshizawa Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1133-8. PubMed ID: 18633251
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
7. Rationale for non-platinum chemotherapy in advanced NSCLC.
Murren JR
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
[TBL] [Abstract][Full Text] [Related]
8. Second and third line treatment in advanced non-small cell lung cancer.
Favaretto AG; Pasello G; Magro C
Discov Med; 2009 Dec; 8(43):204-9. PubMed ID: 20040271
[TBL] [Abstract][Full Text] [Related]
9. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Maráz A; Furák J; Pálföldi R; Eller J; Szántó E; Kahán Z; Thurzó L; Molnár J; Tiszlavicz L; Hideghéty K
Anticancer Res; 2011 Apr; 31(4):1431-6. PubMed ID: 21508398
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization with chemotherapeutic agents.
Caffo O
Lung Cancer; 2001 Dec; 34 Suppl 4():S81-90. PubMed ID: 11742709
[TBL] [Abstract][Full Text] [Related]
11. Development of docetaxel in advanced non-small-cell lung cancer.
Belani CP; Eckardt J
Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
[TBL] [Abstract][Full Text] [Related]
12. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
[TBL] [Abstract][Full Text] [Related]
15. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
16. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
17. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Bunn PA; Kelly K
Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
[TBL] [Abstract][Full Text] [Related]
18. [Carboplatin].
Watanabe H
Nihon Rinsho; 2002 May; 60 Suppl 5():366-9. PubMed ID: 12101690
[No Abstract] [Full Text] [Related]
19. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Maemondo M; Inoue A; Sugawara S; Harada T; Minegishi Y; Usui K; Miwa K; Morikawa N; Kambe M; Ube K; Watanabe K; Ishimoto O; Sakakibara T; Gemma A; Nukiwa T
Oncologist; 2014 Apr; 19(4):352-3. PubMed ID: 24682465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
